OneMedNet Corp ONMD
is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data ("iRWDTM"). OneMedNet's
innovative solutions connect healthcare providers and patients satisfying a crucial need within the life sciences field offering direct
access to clinical images and the associated contextual patient record. OneMedNet's innovative technology proved the commercial
and regulatory viability of imaging Real World Data (as defined below), an emerging market, and provides regulatory-grade image-centric
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- Emea
- Americas
- Asia Pacific
| Region | FY2025 |
|---|---|
| Emea | $695.0K |
| Americas | $608.0K |
| Asia Pacific | $56.0K |
As the company reported it, from the “Schedule of Revenue by Geographic Region (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.4M | $643.0K | $1.0M | $1.2M | — | — |
| Cost of revenue | $1.9M | $924.0K | $1.1M | $1.5M | — | — |
| Gross profit | -$503.0K | -$281.0K | -$129.0K | -$360.0K | — | — |
| R&D | $1.5M | $1.5M | $2.1M | $1.6M | — | — |
| SG&A | $6.4M | $7.0M | $3.5M | $4.8M | — | — |
| Total operating expenses | $9.2M | $9.3M | $6.7M | $7.4M | — | — |
| Operating income | -$9.7M | -$9.6M | -$6.9M | -$7.7M | — | — |
| Interest expense | $67.0K | $147.0K | $11.0K | $403.3K | — | — |
| Pre-tax income | -$2.8M | -$10.1M | -$33.8M | -$30.4M | — | — |
| Income tax | $1.0K | $2.0K | $18.0K | $17.0K | — | — |
| Net income | -$2.8M | -$10.1M | -$33.8M | -$30.5M | — | — |
| EPS, basic | -0.06 | -0.36 | -4.65 | -7.66 | — | — |
| EPS, diluted | -0.06 | -0.36 | -4.65 | -7.66 | — | — |
| Shares, diluted (wtd. avg.) | 44.5M | 28.1M | 7.3M | 4.0M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $585.0K | $172.0K | $47.0K | $271.0K | $453.2K | $0 |
| Receivables | $495.0K | $213.0K | $152.0K | $19.0K | — | — |
| Total current assets | $2.1M | $3.6M | $365.0K | $391.0K | $536.2K | — |
| Property, plant and equipment | $56.0K | $108.0K | $99.0K | $83.0K | — | — |
| Total assets | $2.2M | $3.7M | $464.0K | $1.3M | $117.9M | — |
| Accounts payable | $3.5M | $6.0M | $4.7M | $1.2M | — | — |
| Short-term debt | $974.0K | $9.4M | $465.0K | — | — | — |
| Total current liabilities | $4.8M | $19.2M | $13.8M | $26.1M | $290.0K | — |
| Long-term debt | $220.0K | $2.3M | $465.0K | — | — | — |
| Total liabilities | $5.1M | $19.7M | $13.9M | $27.6M | $9.2M | — |
| Retained earnings | -$104.4M | -$101.6M | -$91.4M | -$57.7M | -$8.6M | — |
| Total equity | -$3.0M | -$15.9M | -$13.4M | -$26.4M | -$7.1M | $0 |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7.5M | -$7.0M | -$4.8M | -$4.7M | — | — |
| Depreciation and amortisation | $65.0K | $57.0K | $28.0K | $25.0K | — | — |
| Stock-based compensation | $2.0M | $628.0K | $1.5M | $1.9M | — | — |
| Capital expenditure | $13.0K | $51.0K | $44.0K | $58.0K | — | — |
| Investing cash flow | $2.3M | -$2.0M | -$44.0K | -$58.0K | — | — |
| Financing cash flow | $5.6M | $9.1M | $4.6M | $4.3M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-032512.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $1.2M | $1.0M | $643.0K | $1.4M |
| Gross profit | — | — | -$360.0K | -$129.0K | -$281.0K | -$503.0K |
| Net income | — | — | -$30.5M | -$33.8M | -$10.1M | -$2.8M |
Recent filings and events
- Director nominations Dates and mechanics for shareholders proposing directors. Item 5.08
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event Item 8.01
- Other event Item 8.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8731
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IQV | IQVIA HOLDINGS INC. | $46.63B | 35.6x | 5.9% |
| INCY | INCYTE CORP | $23.12B | 18.1x | 21.2% |
| MEDP | Medpace Holdings, Inc. | $18.68B | 43.8x | 20.0% |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $16.49B | — | -0.9% |
| ABSI | Absci Corp | $1.58B | — | -38.2% |
| OABI | OmniAb, Inc. | $677.5M | — | -29.3% |
| NRC | NRC HEALTH | $485.1M | 0.4x | -4.0% |
| MXCT | MAXCYTE, INC. | $144.5M | — | -5.7% |